ProCE Banner Activity

Considerations for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Clinical Thought

Are you using quadruple-drug regimens for your patients with transplant-eligible multiple myeloma? Read this commentary for an expert overview of the latest data supporting the addition of an anti-CD38 monoclonal antibody to standard-of-care triplet drug regimens.

Released: May 02, 2024

Expiration: May 01, 2025

Share

Faculty

Charise Gleason

Charise Gleason, MSN, NP-C, AOCNP

VP and Chief APP Officer
Emory Healthcare
NP Myeloma Program Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Faculty Disclosure

Primary Author

Charise Gleason, MSN, NP-C, AOCNP

VP and Chief APP Officer
Emory Healthcare
NP Myeloma Program Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Charise Gleason, MSN, NP-C, AOCNP: consultant/advisor/speaker: Pfizer.